
-
AC Immune SA NasdaqGM:ACIU AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Location: Building B, Building B, Lausanne, 1015, Switzerland | Website: https://www.acimmune.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
31.26M
Cash
145.6M
Avg Qtr Burn
N/A
Short % of Float
3.59%
Insider Ownership
38.01%
Institutional Own.
26.11%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PI-2620 Details Neurological disorder, Alzheimer's disease | Phase 3 Data readout | |
JNJ-2056 (prev. ACI-35.030 or JACI-35.054) Details Neurological disorder, Alzheimer's disease | Phase 2b Data readout | |
ACI-7104.056 Details Parkinson's disease | Phase 2 Data readout | |
Crenezumab Details Alzheimer's disease, Neurological disorder | Phase 2 Update | |
Semorinemab Details Neurological disorder, Alzheimer's disease | Phase 2 Update | |
ACI-24.060 (anti-Abeta vaccine) Details Neurological disorder, Alzheimer's disease, Down Syndrome | Phase 1/2 Data readout | |
ACI-19626 (TDP-43-PET tracer) Details Frontotemporal dementia | Phase 1 Data readout | |
ACI-15916 (a-syn-PET tracer) Details Parkinson's disease | Phase 1 Data readout | |
AC1-3024 Details Neurological disorder | Failed Discontinued |